Intellia Therapeutics, Inc.
NTLA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NTLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NTLA
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company focused on developing potentially curative genome editing treatments using its modular platform, with lead programs in transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE).
Key risk: Clinical trial risks
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.80B
Cash Runway
16.2 moLead Asset
lonvoguran ziclumeran (Phase 3)
Next Catalyst
Phase3_Topline · Sep 1, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 3 catalysts for Intellia Therapeutics, Inc..
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company focused on developing potentially curative genome editing treatments using its modular platform, with lead programs in transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE).
- Reported positive topline data from the global Phase 3 HAELO clinical trial of lonvo-z in HAE, with preparations underway for a planned commercial launch in the first half of 2027, if approved [sec_mda · as of 2026-08-06].
- Announced first clinical evidence from an ongoing Phase 1 study that nex-z may favorably impact disease progression in ATTR [sec · filed 2025-04-30].
- Cash, cash equivalents and marketable securities of $106.1M as of June 30, 2026, with expectations to fund operations at least into 2028 [sec_mda · as of 2026-08-06].
- Net loss of $106.6M for the quarter ended June 30, 2026, with total revenue of $7.7M [latest reported financials (authoritative, structured) as of 2026-06-30].
- Shareholders' equity was negative $715.3M as of June 30, 2026 [latest reported financials (authoritative, structured) as of 2026-06-30].
What works
- Positive Phase 3 HAELO topline data for lonvo-z in HAE supports potential regulatory submission and commercial launch in first half of 2027 [sec_mda · as of 2026-08-06].
- First clinical evidence from Phase 1 study suggests nex-z may favorably impact disease progression in ATTR [sec · filed 2025-04-30].
- Cash runway extended into 2028, providing financial flexibility for key clinical milestones [sec_mda · as of 2026-08-06].
- Strategic collaboration with ReCode Therapeutics to develop gene editing therapies for cystic fibrosis [sec · filed 2025-04-30].
What to weigh
- Net loss of $106.6M for the quarter ended June 30, 2026, with negative shareholders' equity of $715.3M [latest reported financials (authoritative, structured) as of 2026-06-30].
- Dependence on additional financing to support operations; may need to delay or reduce programs if funds are insufficient [sec_mda · as of 2026-08-06].
- All revenue to date has been collaboration revenue, with no approved products generating commercial sales [sec_mda · as of 2025-08-07].
From the filings
Quoted directly from source documents.
Positive Phase 3 HAELO topline data for lonvo-z in HAE
“reported positive topline data from the global Phase 3 HAELO clinical trial of lonvo-z in HAE”
SEC MD&A · August 6, 2026
First clinical evidence that nex-z may favorably impact disease progression in ATTR
“Announced first clinical evidence from ongoing Phase 1 study that nex-z may favorably impact disease progression in ATTR”
SEC filings · April 30, 2025
Cash runway at least into 2028
“will enable us to fund our ongoing operating expenses and capital expenditure requirements at least into 2028”
SEC MD&A · August 6, 2026
All revenue to date has been collaboration revenue
“All of our revenue to date has been collaboration revenue.”
SEC MD&A · August 7, 2025
Catalyst timeline
- 2027-09-01 · Phase3_Topline — Phase 3 Topline: HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the — Topline data from the HAELO study of lonvo-z in HAE; positive data already reported, but this may refer to additional analyses or regulatory milestones.
- 2028-04-01 · Phase3_Topline — Phase 3 Topline: MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study — Topline data from the MAGNITUDE study of nex-z in ATTR cardiomyopathy.
- 2028-08-01 · Phase3_Topline — Phase 3 Topline: MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluat — Topline data from the MAGNITUDE-2 study of nex-z in ATTR polyneuropathy.
Risks & what to watch (4)›
Key risks
- Clinical trial risks — Phase 3 trials for nex-z (HAELO, MAGNITUDE, MAGNITUDE-2) may fail to meet endpoints, delaying or preventing approval [catalyst].
- Financial sustainability — Net loss of $106.6M and negative equity of $715.3M as of June 30, 2026, with reliance on future financing [latest reported financials].
- Commercialization execution — Planned launch of lonvo-z in HAE in first half of 2027 depends on regulatory approval and market adoption [sec_mda · as of 2026-08-06].
- Dependence on collaborations — All revenue to date is from collaborations; loss of key partners could impact pipeline funding [sec_mda · as of 2025-08-07].
What to watch
- Phase 3 HAELO topline data for lonvo-z in HAE (reported positive) and subsequent regulatory submission [sec_mda · as of 2026-08-06].
- Phase 3 MAGNITUDE and MAGNITUDE-2 topline data for nex-z in ATTR, expected in 2028 [catalyst].
- Commercial launch of lonvo-z in HAE in first half of 2027, if approved [sec_mda · as of 2026-08-06].
- Cash burn rate and any additional equity offerings or partnership deals to extend runway [sec_mda · as of 2026-08-06].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Intellia Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Intellia Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
16.2 months
D/E 0.18 · 0% dilution
Lead: Phase 3
2 candidates
3 upcoming, next in ~367d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
306
Total value held
$1.49B
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 14,509,247 | $186.0M |
| blackrock, inc. | 12,155,806 | $155.8M |
| vanguard capital management llc | 10,168,210 | $130.4M |
| state street corp | 6,922,676 | $88.7M |
| vanguard portfolio management llc | 6,223,325 | $79.8M |
| d. e. shaw & co., inc. | 5,728,177 | $73.4M |
| two sigma investments, lp | 4,705,901 | $60.3M |
| regeneron pharmaceuticals, inc. | 3,702,995 | $47.5M |
| geode capital management, llc | 2,851,472 | $36.6M |
| susquehanna international group, llp | 2,702,665 | $34.6M |
Showing top 10 of 306 institutional holders of Intellia Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 36.8%
- Days to cover
- 12.4
- Shares short
- 38,812,013
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NTLA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company focused on developing potentially curative genome editing treatments using its modular platform, with lead programs in transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE).
What is Intellia Therapeutics, Inc.'s lead drug candidate?
Intellia Therapeutics, Inc.'s most advanced tracked candidate is lonvoguran ziclumeran (Phase 3) for Neuromuscular Disease.
What is Intellia Therapeutics, Inc.'s next catalyst?
Intellia Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the " — expected September 1, 2027.
Who is the CEO of Intellia Therapeutics, Inc.?
Dr. John M. Leonard M.D. is the chief executive officer of Intellia Therapeutics, Inc. (NTLA).
Where is Intellia Therapeutics, Inc. headquartered?
Intellia Therapeutics, Inc. (NTLA) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.